Tekmira Pharmaceuticals Corporation's LNP Technology Highlighted in Peer-Reviewed Publication, Cancer Discovery

Published: Feb 01, 2013

VANCOUVER, British Columbia, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that complete study results have been published from a Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement, which utilizes Tekmira's lipid nanoparticle (LNP) technology. ALN-VSP is being developed by Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY).

Back to news